Key Drivers
- Revenue Growth
- Cash Burn
- Leverage Pressure
AIAI Summary
PGEN has shifted from a pipeline story to a real commercialization test, with PAPZIMEOS driving meaningful revenue and high gross margins, but the stock remains a high-risk hold until that growth is strong enough to overcome persistent cash burn, leverage, and dependence on a single product.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Revenue Growth
- •Cash Burn
- •Leverage Pressure
PGEN improved revenue and gross margin in the quarter, but persistent losses, negative cash flow, high leverage, and elevated valuation keep the stock high-risk.
Price Behavior
Key Price Behavior Insights:
- •Higher Lows
- •Breakout Attempt
- •Choppy Advance
Over the last month, PGEN has built a modest uptrend with higher lows and an attempted breakout above $4.20, but choppy trading and resistance near $4.60 mean it must hold $4.20 to reduce the risk of a slide back toward $4.00 support.
Sharp reversals in late
Sentiment & News
Key News Insights:
- •PAPZIMEOS traction
- •Cash runway
- •ASCO catalyst
Precigen's Q1 2026 results beat expectations, led by accelerating PAPZIMEOS sales and improving confidence in reaching cash flow break-even by year-end.
The update is modestly positive for PGEN, as early PAPZIMEOS commercialization and upcoming clinical catalysts may support further upside if launch momentum continues
Similar Companies in Healthcare
Other companies in the same sector with AI ratings